You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

riTUXimab

( rit-TUCKS-ee-mab )
Other Name(s): Rituxan®; Truxima™; Riximyo™; Ruxience™; Riabni™
Appearance: Clear, colourless solution mixed into larger bags of fluids

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Drug Monograph

Oct 2023

Patient Info Sheet

Oct 2023

What it is used for

  • For treating blood cancers such as non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL)
     
  • Rituximab is available as a biosimilar medication. See our biosimilar pamphlet for more information. 


You might also be interested in